RR and 95% CI values for the association between recent weight change (1982-1992) and prostate cancer incidence (CPS-II Nutrition Cohort, 1992-2003)
. | Recent weight change from 1982-1992 (pounds) . | . | . | . | . | . | . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Weight loss . | . | . | Loss or gain . | Weight gain . | . | . | |||||||
. | −21+ . | −11 to −20 . | −6 to −10 . | −5 to 5 . | 6-10 . | 11-20 . | 21+ . | |||||||
All cases | ||||||||||||||
No. of cases* | 113 | 349 | 541 | 2,450 | 751 | 687 | 322 | |||||||
Person-years | 12,624 | 36,330 | 47,110 | 211,790 | 68,515 | 65,495 | 35,227 | |||||||
RR (95% CI)† | 0.76 (0.63-0.92) | 0.81 (0.72-0.90) | 0.97 (0.89-1.07) | 1.00 (ref) | 0.97 (0.89-1.05) | 0.95 (0.87-1.03) | 0.85 (0.75-0.95) | |||||||
RR (95% CI)‡ | 0.83 (0.69-1.01) | 0.84 (0.75-0.94) | 0.98 (0.89-1.08) | 1.00 (ref) | 0.98 (0.90-1.06) | 0.96 (0.88-1.05) | 0.88 (0.79-0.99) | |||||||
RR (95% CI)§ | 0.84 (0.69-1.02) | 0.84 (0.75-0.95) | 0.98 (0.89-1.08) | 1.00 (ref) | 0.98 (0.90-1.06) | 0.97 (0.89-1.05) | 0.89 (0.79-1.00) | |||||||
Nonmetastatic low grade∥ | ||||||||||||||
No. of cases* | 83 | 284 | 427 | 1,908 | 606 | 545 | 251 | |||||||
Person-years | 12,624 | 36,330 | 47,110 | 211,790 | 68,515 | 65,495 | 35,227 | |||||||
RR (95% CI)† | 0.73 (0.58-0.91) | 0.86 (0.76-0.97) | 1.00 (0.90-1.11) | 1.00 (ref) | 1.00 (0.91-1.09) | 0.95 (0.86-1.05) | 0.83 (0.73-0.95) | |||||||
RR (95% CI)‡ | 0.81 (0.65-1.01) | 0.90 (0.79-1.02) | 1.01 (0.91-1.12) | 1.00 (ref) | 1.01 (0.92-1.10) | 0.97 (0.88-1.07) | 0.88 (0.77-1.00) | |||||||
RR (95% CI)§ | 0.85 (0.68-1.06) | 0.91 (0.81-1.04) | 1.01 (0.91-1.13) | 1.00 (ref) | 1.01 (0.92-1.11) | 0.98 (0.89-1.08) | 0.89 (0.78-1.02) | |||||||
Nonmetastatic high grade∥ | ||||||||||||||
No. of cases* | 45 | 66 | 332 | 87 | 129 | |||||||||
Person-years | 48,954 | 47,110 | 211,790 | 68,515 | 100,722 | |||||||||
RR (95% CI)† | 0.56 (0.41-0.77)¶ | 0.86 (0.66-1.12) | 1.00 (ref) | 0.84 (0.66-1.07) | 0.88 (0.72-1.08)** | |||||||||
RR (95% CI)‡ | 0.58 (0.42-0.79)¶ | 0.86 (0.66-1.12) | 1.00 (ref) | 0.85 (0.67-1.07) | 0.90 (0.73-1.11)** | |||||||||
RR (95% CI)§ | 0.55 (0.40-0.75)¶ | 0.85 (0.65-1.10) | 1.00 (ref) | 0.84 (0.67-1.07) | 0.88 (0.71-1.08)** | |||||||||
Stage D or fatal cases | ||||||||||||||
No. of cases* | 31 | 28 | 137 | 33 | 57 | |||||||||
Person-years | 48,954 | 47,110 | 211,790 | 68,515 | 100,722 | |||||||||
RR (95% CI)† | 0.85 (0.58-1.26)¶ | 0.82 (0.55-1.24) | 1.00 (ref) | 0.81 (0.55-1.18) | 1.02 (0.75-1.39)** | |||||||||
RR (95% CI)‡ | 0.87 (0.59-1.30)¶ | 0.84 (0.56-1.26) | 1.00 (ref) | 0.80 (0.55-1.17) | 0.99 (0.72-1.35)** | |||||||||
RR (95% CI)§ | 0.83 (0.56-1.24)¶ | 0.83 (0.55-1.24) | 1.00 (ref) | 0.80 (0.54-1.17) | 0.97 (0.71-1.33)** |
. | Recent weight change from 1982-1992 (pounds) . | . | . | . | . | . | . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Weight loss . | . | . | Loss or gain . | Weight gain . | . | . | |||||||
. | −21+ . | −11 to −20 . | −6 to −10 . | −5 to 5 . | 6-10 . | 11-20 . | 21+ . | |||||||
All cases | ||||||||||||||
No. of cases* | 113 | 349 | 541 | 2,450 | 751 | 687 | 322 | |||||||
Person-years | 12,624 | 36,330 | 47,110 | 211,790 | 68,515 | 65,495 | 35,227 | |||||||
RR (95% CI)† | 0.76 (0.63-0.92) | 0.81 (0.72-0.90) | 0.97 (0.89-1.07) | 1.00 (ref) | 0.97 (0.89-1.05) | 0.95 (0.87-1.03) | 0.85 (0.75-0.95) | |||||||
RR (95% CI)‡ | 0.83 (0.69-1.01) | 0.84 (0.75-0.94) | 0.98 (0.89-1.08) | 1.00 (ref) | 0.98 (0.90-1.06) | 0.96 (0.88-1.05) | 0.88 (0.79-0.99) | |||||||
RR (95% CI)§ | 0.84 (0.69-1.02) | 0.84 (0.75-0.95) | 0.98 (0.89-1.08) | 1.00 (ref) | 0.98 (0.90-1.06) | 0.97 (0.89-1.05) | 0.89 (0.79-1.00) | |||||||
Nonmetastatic low grade∥ | ||||||||||||||
No. of cases* | 83 | 284 | 427 | 1,908 | 606 | 545 | 251 | |||||||
Person-years | 12,624 | 36,330 | 47,110 | 211,790 | 68,515 | 65,495 | 35,227 | |||||||
RR (95% CI)† | 0.73 (0.58-0.91) | 0.86 (0.76-0.97) | 1.00 (0.90-1.11) | 1.00 (ref) | 1.00 (0.91-1.09) | 0.95 (0.86-1.05) | 0.83 (0.73-0.95) | |||||||
RR (95% CI)‡ | 0.81 (0.65-1.01) | 0.90 (0.79-1.02) | 1.01 (0.91-1.12) | 1.00 (ref) | 1.01 (0.92-1.10) | 0.97 (0.88-1.07) | 0.88 (0.77-1.00) | |||||||
RR (95% CI)§ | 0.85 (0.68-1.06) | 0.91 (0.81-1.04) | 1.01 (0.91-1.13) | 1.00 (ref) | 1.01 (0.92-1.11) | 0.98 (0.89-1.08) | 0.89 (0.78-1.02) | |||||||
Nonmetastatic high grade∥ | ||||||||||||||
No. of cases* | 45 | 66 | 332 | 87 | 129 | |||||||||
Person-years | 48,954 | 47,110 | 211,790 | 68,515 | 100,722 | |||||||||
RR (95% CI)† | 0.56 (0.41-0.77)¶ | 0.86 (0.66-1.12) | 1.00 (ref) | 0.84 (0.66-1.07) | 0.88 (0.72-1.08)** | |||||||||
RR (95% CI)‡ | 0.58 (0.42-0.79)¶ | 0.86 (0.66-1.12) | 1.00 (ref) | 0.85 (0.67-1.07) | 0.90 (0.73-1.11)** | |||||||||
RR (95% CI)§ | 0.55 (0.40-0.75)¶ | 0.85 (0.65-1.10) | 1.00 (ref) | 0.84 (0.67-1.07) | 0.88 (0.71-1.08)** | |||||||||
Stage D or fatal cases | ||||||||||||||
No. of cases* | 31 | 28 | 137 | 33 | 57 | |||||||||
Person-years | 48,954 | 47,110 | 211,790 | 68,515 | 100,722 | |||||||||
RR (95% CI)† | 0.85 (0.58-1.26)¶ | 0.82 (0.55-1.24) | 1.00 (ref) | 0.81 (0.55-1.18) | 1.02 (0.75-1.39)** | |||||||||
RR (95% CI)‡ | 0.87 (0.59-1.30)¶ | 0.84 (0.56-1.26) | 1.00 (ref) | 0.80 (0.55-1.17) | 0.99 (0.72-1.35)** | |||||||||
RR (95% CI)§ | 0.83 (0.56-1.24)¶ | 0.83 (0.55-1.24) | 1.00 (ref) | 0.80 (0.54-1.17) | 0.97 (0.71-1.33)** |
Case numbers may not sum to total 5,252 due to exclusions of extreme values of weight in 1982 and missing data.
Adjusted for age at interview.
Adjusted for age at interview, race, education, family history of prostate cancer, total calorie intake, smoking status, history of PSA testing, history of diabetes, height, and physical activity.
Adjusted for age at interview, race, education, family history of prostate cancer, total calorie intake, smoking status, history of PSA testing, history of diabetes, height, physical activity, and BMI in 1982.
One hundred and sixty-four nonmetastatic low-grade cases excluded due to missing Gleason score information.
This value is for the weight loss of −11 to −20 and −21+ groups combined.
This value is for the weight gain of 11 to 20 and 21+ groups combined.